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A B S T R A C T
The infections caused by Pseudomonas aeruginosa are life-threatening, due to high intrinsic antimicrobial re-
sistance of this microorganism. The integrons and bioﬁlm formation of P. aeruginosa have a signiﬁcant role in
antibiotic resistance. Therefore, this study aimed to evaluate antibiotic resistance pattern in Pseudomonas aer-
uginosa isolates with bioﬁlm formation ability. This cross-sectional study from January 2017 to December 2017
was conducted on 78 isolates (58 clinical and 20 environmental) of P. aeruginosa recovered from the 547 samples
(439 of clinical and 108 of environmental samples). The isolates were identiﬁed by phenotypic and genotypic
tests. Kirby-Bauer disk diﬀusion method was used for susceptibility testing. The prevalence of class 1, 2 and 3
Integrons, rhlA, and lasB genes were determined using Polymerase Chain Reaction (PCR). Bioﬁlm formation was
determined using the microtiter plate method. Data analyzed using Stata 14 software and Chi-Square test.
The most prevalent resistance was observed against Ticarcillin/Clavulanic Acid (55%). Generally, 56.4% of
isolates were producers of strong bioﬁlm in both environmental and clinical isolates. The prevalence of strong
bioﬁlm producers in clinical isolates was more than environmental. A signiﬁcant correlation was observed be-
tween Int1, Int2, and rhlA genes with bioﬁlm formation capability (P=0.02).
Regarding>50% of both environmental and clinical isolates were producers of strong bioﬁlm and because
the source of clinical isolates may be from the environment, the necessary hygiene measurements should be
taken. No signiﬁcant correlation was observed between lasB gene with bioﬁlm formation capability.
1. Introduction
Pseudomonas aeruginosa is a Gram-negative microorganism that is
the third most common cause of nosocomial infections after
Staphylococcus aureus and Escherichia coli (Abbasi et al., 2017). As well
as, it is the main causes of hospital infections, especially in patients with
cystic ﬁbrosis (CF), burns or immunodeﬁciency and those who receive
artiﬁcial ventilation (Arvanitidou et al., 2005).
The widespread use of antibiotics in recent years has caused the P.
aeruginosa be resistant to broad-spectrum antibiotics from diﬀerent
groups (Khaledi and Meskini, 2018), where currently existence of
strains with multi-drug resistance (MDR) is a major concern in coun-
tering with this bacterium in main wards of the hospital, such as the
Burn and Intensive Care Units (ICU) (Nakhjavani, 2008). Nosocomial
infection is one of the main problems of medicine in developed and also
developing countries, which promotes the spread of infectious diseases
in the community (Abbasi et al., 2017; Khaledi et al., 2016b). Patients
who have burn wound have a higher sensitivity to infection with mi-
croorganisms due to the weakened immune system results from loss of
skin defenses and burn injuries (Rossolini and Mantengoli, 2005).
In recent years, a wide prevalence of MDR P. aeruginosa strains has
been reported worldwide (Magiorakos et al., 2012). Diﬀerent factors
play a role in the resistance of bacteria against antibiotics such as; the
permeability of microorganisms to antibiotics, the existence of eﬄux
pumps, the change in receptors of microorganisms for antibiotics, and
the production of beta-lactamase enzymes (Fajardo and Martínez,
https://doi.org/10.1016/j.genrep.2019.100561
Received 26 October 2019; Received in revised form 6 November 2019; Accepted 8 November 2019
Abbreviations: CF, cystic ﬁbrosis; MDR, multi-drug resistance; ICU, Intensive Care Unit; TSB, Trypticase soy broth
⁎ Corresponding author.
E-mail address: alikhani@umsha.ac.ir (M.Y. Alikhani).
Gene Reports 18 (2020) 100561
Available online 09 November 2019
2452-0144/ © 2019 Elsevier Inc. All rights reserved.
T
2008). It has been well established that a large spectrum of these re-
sistance patterns is generated by the acquisition of other genetic ele-
ments such as transposon, phage, and mobile gene cassettes containing
resistant genes (Khaledi et al., 2016a). These mobile genetic elements
have a high potential for transferring drug resistance genes (Svara and
Rankin, 2011). There are several classes of integrons, among which
classes 1, 2, and 3, especially class 1 have a signiﬁcant role in the an-
tibiotic resistance (Hall and Collis, 1995).
In P. aeruginosa, Metallo-β-lactamase (MBL) are encoded by mobile
genetic elements, including class 1 and 2 integrons (Pournaras et al.,
2002). Another cause of resistance to P. aeruginosa is the bioﬁlms for-
mation. The bioﬁlms do not degrade with antibacterial agents such as
disinfectants, heating, drying, and remain on the surfaces, in particular,
in hospitals and can cause contamination and transmission of infectious
diseases. Bioﬁlm acts as a barrier to the immune system and antibiotics,
which is the main cause of infectious diseases (Branda et al., 2005). The
genes such as rhlA and lasB are accounted for Quorum Sensing and the
bioﬁlm formation of P. aeruginosa (Khairy et al., 2013). As the begin-
ning of lasB activity is linked with the start of the initial development of
bioﬁlm (Sauer et al., 2002). The next step in bioﬁlm expansion was
maturation. In which, the second quorum-sensing regulon (rhlA) have a
signiﬁcant role (Davies et al., 1998). Because P. aeruginosa has a chief
role in producing hospital infections, especially in burn patients,
knowledge of how these strains are disseminated has a special epide-
miological importance to ﬁnd the source of infection.
Accordingly, this study aimed to evaluate antibiotic resistance pat-
tern in Pseudomonas aeruginosa isolates with bioﬁlm formation ability.
2. Material and methods
2.1. Ethics statement
The Ethics Committee of Hamadan University of Medical Sciences
approved the current study protocol (IR.UMSHA.REC.1395.109).
2.2. Collection of specimens
This cross-sectional study with consecutive sampling from January
2017 to December 2017 was conducted. In total, 439 clinical specimens
(urine, blood, wounds, Cerebrospinal ﬂuid) of patients with nosocomial
(Urinary tract infection, Wound infection, soft tissue and skin infec-
tions, Bacteremia) infections admitted in the burn ward of Besat
Hospital of Hamadan, Iran, were achieved. Also, 108 environmental
samples were collected from the environment (beds, patients' clothing,
tap water, and sink). Samples were transferred to the Microbiology
Laboratory of the Faculty of Medicine. Finally, isolates were detected
and identiﬁed by microbiology and biochemical tests (Alikhani et al.,
2014). In addition to phenotypic methods, genotypic conﬁrmation of
isolates was done by the presence of toxA gene (Frank et al., 1989). In
total, 78 (58 clinical and 20 environmental isolates) of P. aeruginosa
were retrieved.
2.3. Susceptibility testing
Antimicrobial susceptibility was determined using the Kirby-Bauer
agar disk diﬀusion method (Goel et al., 2013). Brieﬂy, pure colonies
were taken and inoculated to broth culture (Soybean-Casein Digest
Medium). Inoculation was made with a broth culture Soybean-Casein
Digest Medium (HiMedia BioSciences Company) diluted to match a 0.5
McFarland turbidity standard. Using an aseptic technique, a sterile
swab placed into the broth culture of a speciﬁc organism and then
gently remove the excess liquid by gently pressing or rotating the swab
against the inside of the tube. Using the swab, the Mueller-Hinton agar
plate streaked to form a bacterial lawn. To obtain uniform growth, the
plate streaked with a swab in one direction, rotated the plate 90° and
streaked the plate again in that direction. Repeat this rotation 3 times.
Allow the plate to dry for approximately 5min. An antibiotic disc dis-
penser was used to dispense discs containing speciﬁc antibiotics onto
the plate. Using a ﬂame-sterilized forceps gently pressed each disc to
the agar to ensure that the disc was attached to the agar. Then, plates
were incubated overnight at an incubation temperature of 37 °C. The
diameter of the zones of inhibition was measured using a ruler. Finally,
the results interpreted as susceptible, intermediate, and resistance ac-
cording to the Clinical and Laboratory Standard Institute guidelines.
Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as
quality control strains. The Susceptibility proﬁles were determined for
Ceftazidime (30 μg), efepime (30 μg), Ciproﬂoxacin (5 μg), Imipenem
(10 μg), Meropenem (10 μg), Piperacillin-tazobactam (30 μg), Ti-
carcillin-clavulanic acid (75/10 μg), Tobramycin (10 μg), Colistin
(10 μg), Aztreonam (30 μg), Amikacin (30 μg), and Gentamicin (30 μg)
antibiotics (Mast Company, UK).
2.4. Detection of genes by PCR technique
DNA of clinical isolates was extracted using a DNA extraction kit
(Merck Company, German) and the frequency of classes 1, 2, and 3
integrons, rhlA, and lasB genes were determined in isolates using PCR.
Brieﬂy, PCR assays for detection of class 1, 2, 3 integrons, toxA, rhlA,
and lasB genes were performed using suitable primers (Gu et al., 2007)
as listed in Table 1. PCR was conducted in 25 μL of ﬁnal reaction vo-
lume. The reaction contained 2 μL of DNA template, PCR Master Mix
(12.5 μL), each primer (10 pmol) with volume 1 μL. PCR conditions
were; Initial denaturation (94 °C for 5min), followed by 35 cycles of
denaturation (94 °C for 60 s), an annealing temperature for each gene
(according to Table 1) for 1min, an extension at 72 °C for 45 s, and a
ﬁnal extension at 72 °C for 5min.
2.5. Bioﬁlm production assay
The bioﬁlm formation was determined using a microtiter plate
Table 1
The primers used in this study for detection of toxA, Integrons, and bioﬁlm-related genes.
Genes (Sequence) 5′–3′ Length (bp) Annealing temperature Reference
toxA F: 5′-GGTAGTTGGTCGCTGAAC-3′
R:5′-GACGAAGAAGGTGGCATC-3′
177 62 °C This study
Int1 F: 5′- CACGGATATGCGACAAAAAG-3′
R: 5′-GATGACAACGAGTGACGAAATG_3′
160 51 °C Gu et al. (2007)
Int2 F: 5′- CACGGATATGCGACAAAAAG-3′
R: 5′-GATGACAACGAGTGACGAAATG_3′
787 51 °C
Int3 F: 5′-GCCTCCGGCAGCGACTTTCAG_3′
R: 5′-ACGGATCTGCCAAACCTGACT_3′
980 51 °C
lasB F: 5′-AATGACAAAGTGGAACTGGTGATCC-3′
R: 5′-GTAGGTGTACTTGCCGATCTTCTGG-3′
213 62 °C Van Belkum et al. (1998)
RhlA F: 5′- TGCTGATGGTTGCTGGCTTTC -3′
R: 5′- CTCGGTGGTGATGGCATTCG-3′
89 52 °C This study
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method. In brief, after adding bacteria to micro-plates containing 200
uL of Luria Bertani medium (HiMedia BioSciences Company) incubated
overnight. Then, Safranin dye was used for staining (O'Toole et al.,
1999). The absorbance was measured at a wavelength of 560 nm. The
Trypticase soy broth (HiMedia BioSciences Company) with no bac-
terium was used as a negative control. Finally, for the interpretation of
bioﬁlm formation, the criteria of Stepannovic et al. was used (Bardbari
et al., 2017). For determining bioﬁlm, the following values were ap-
plied:
Non-bioﬁlm producer: OD 560 < 0.275.
Weak bioﬁlm producer: 0.275≤OD 560 < 0.55.
Medium bioﬁlm producer: 0.55≤OD 560 < 0.825.
Strong bioﬁlm producer: 0.825≤OD560.
2.6. Statistical analysis
Statistical analysis was performed using Stata 14 software. The rate
of some parameters such as positive cultures of P. aeruginosa, suscept-
ibility, Integrons type genes, and bioﬁlm-related genes were categor-
ized. The relationship between bioﬁlm formation capability, the oc-
currence of bioﬁlm-related genes of P. aeruginosa in both of two groups
or between of them and relationship between the origin of P. aeruginosa
isolates and certain features (e.g. resistance pattern) were assessed by
Chi-Square. Statistically signiﬁcant level for all of the testes was con-
sidered at P < 0.05.
3. Results
3.1. Distribution of isolates in clinical and environmental samples
In total, 78 isolates of P. aeruginosa were recovered from both
clinical wards (n= 58) and environment (n= 20). Distribution of
clinical specimens was as follows; Urine (n=24), blood (n=12),
wound (n=13), CSF (n= 9). As well, frequency of environmental
samples came from close proximity to the infected patients was as
follows; beds (n= 5), patientsˈ clothing (n=4), tap water (n= 5), and
sink (n=6).
Thirty-four (58.6%) and 24 (41.4%) of patients were males and
females, respectively. The mean age of males and females was 39.7 and
25.3 years, respectively.
3.2. Results of susceptibility testing
As presented in Table 2,> 50% of clinical and environmental iso-
lates were resistant to all of the used antibiotics. In clinical isolates, the
most resistance has been observed against Ticarcillin/Clavulanic Acid
(75.8%) followed by Aztreonam with 72.4% resistance. Also, in en-
vironmental isolates, the most prevalent resistance was seen against
mentioned antibiotics (55%). 62.8% of isolates (67.2% clinical and 50%
of environmental) were MDR and 37.2% were Non-MDR (32.8% and
50% of isolates were from clinical and environmental, respectively).
3.3. Association of bioﬁlm formation with antibiotic resistance
According to data abstracted in Table 3, most of both clinical and
environmental isolates were bioﬁlm producers. Accordingly, bioﬁlm
formation ability of the isolates was categorized as the strong, mod-
erate, weak, and non-bioﬁlm producers. In total, 43 of 78 (55.1%)
isolates were producers of strong bioﬁlm in both environmental and
clinical isolates. About 35 (60.3%) of clinical isolates were strong bio-
ﬁlm producers, and also, 8 (40%) of environmental isolates were pro-
ducers of strong bioﬁlm. Only 3 (3.8%) of both clinical and environ-
mental isolates were non-bioﬁlm producers.
Of total 78 isolates, 49 (62.8%) were MDR, and remaining 29
(37.2%) of isolates were Non-MDR. Overall, 46.8% of MDR isolates
were producers of strong bioﬁlm, of which, 34 (58.6%) were MDR
clinical isolates, and also 7 (35%) were environmental isolates with the
capability to produce bioﬁlm. A signiﬁcant association between MDR
and bioﬁlm formation ability was reported (P=0.00).
3.4. Bioﬁlm-related genes, integrons, and correlation with bioﬁlm formation
Among clinical isolates of P. aeruginosa, the prevalence of genes;
lasB, rhlA, Int1, Int2, and Int3 were 54 (93.1%), 56 (96.5%), 36 (63.1%),
16 (27.5%), and 4 (6.9%), respectively. Also, for the same genes in
environmental isolates, the prevalence has reported 20 (100%), 17
(85%), 13 (65%), 6 (30%), and 7 (35%), respectively (Fig. 1).
43 (97.7%) of clinical and environmental isolates containing lasB
gene were strong bioﬁlm producers. Also, 44 (100%) of clinical and
environmental isolates which were positive for rhlA had a strong bio-
ﬁlm formation ability. Overall, producing the strong bioﬁlm between
both types of isolates containing Int1, Int2 and, Int3 was 38 (88.3%), 18
(40.9%), and 8 (18.1%), respectively. Regarding the bioﬁlm formation
capability of most environmental and clinical isolates, a signiﬁcant
correlation was observed between Int1, Int2, and rhlA genes with bio-
ﬁlm formation capability of isolates (P=0.02). Also, no correlation
was found between lasB and Int3 with bioﬁlm formation capability
(P > 0.05), Table 4.
Table 2
The antimicrobial resistance pattern in clinical and environmental isolates of P. aeroginosa.
Co CPM ATM AK PRL CIP CAZ IMI GM MEM TN TIM
Clinical
Susceptible 58 (100) 27 (46.5) 16 (27.5) 30 (51.7) 24 (41.3) 21 (36.2) 30 (51.7) 27 (46.5) 32 (55.1) 28 (48.2) 30 (51.7) 14 (24.1)
Resistance – 31 (53.4) 42 (72.4) 28 (48.2) 34 (58.6) 37 (63.7) 28 (48.2) 31 (53.4) 26 (44.8) 30 (51.7) 28 (48.2) 44 (75.8)
Environmental
Susceptible 20 (100) 10 (50) 9 (45) 11 (55) 11 (55) 10 (50) 11 (55) 10 (50) 9 (45) 12 (60) 12 (60) 9 (45)
Resistance – 10 (50) 11 (55) 9 (45) 9 (45) 10 (50) 9 (45) 10 (50) 11 (55) 8 (40) 8 (40) 11 (55)
Note: CO: Colistin, CPM: Cefepime, ATM: Azteronam, AK: Amikacin, PRL: Piperacilin, CIP: Ciproﬂoxacin, CAZ: Ceftazidime, IMI: Imipenem, GM: Gentamicin, MEM:
Meropenem, TN: Tobramycin, TIM: Ticarcilin/Calvulanic Acid.
Table 3
Correlation between MDR and Non-MDR strains and bioﬁlm formation ability
by the phenotypic method.
Types of bioﬁlm Clinical or
environmental
MDR Non-MDR Total
Strong bioﬁlm
producer
Clinical 34 (58.6%) 1 (1.7%) 35 (60.3%)
Environmental 7 (35%) 1 (5%) 8 (40%)
Moderate bioﬁlm
producer
Clinical 3 (5.2%) 12 (20.8%) 15 (26%)
Environmental 2 (10%) 4 (20%) 6 (30%)
Weak bioﬁlm
producer
Clinical 2 (3.4%) 5 (8.6%) 7 (12%)
Environmental 1 (5%) 3 (15%) 4 (20%)
No bioﬁlm
producer
Clinical 0 (0%) 1 (1.7%) 1 (1.7%)
Environmental 0 (0%) 2 (10%) 2 (10%)
Total Clinical 39 (67.2%) 19 (32.8%) 58 (100%)
Environmental 10 (50%) 10 (50%) 20 (100%)
P-value 0.00 0.2 –
P. Karami, et al. Gene Reports 18 (2020) 100561
3
3.5. Correlation between class 1, 2, and 3 integrons with antibiotic
resistance
As shown in Table 5, there was a signiﬁcant relationship between
Int1 and antibiotic resistance against Cefepime, Aztreonam, Amikacin,
Piperacillin, Ciproﬂoxacin, Ceftazidime, Imipenem, Gentamicin, Mer-
openem, and Tobramycin in clinical isolates (P < 0.05), this mode
there was in environmental isolates (P < 0.05), except such correla-
tion, was not observed against Tobramycin in environmental isolates
(P > 0.05), also, this correlation was not reported between prevalence
of class1 integrons and resistance against Ticarcillin/Clavulanic Acid in
both clinical and environmental isolates (P > 0.05).
Our results showed only statistically signiﬁcant association between
the presence of Int2 and resistance against Aztreonam (P < 0.045),
while, didn't show any association between existence of Int2 and re-
sistance against other antibiotics used in the current study in clinical
isolates (P > 0.05), but in environmental isolates, such a correlation
was observed for Meropenem (P < 0.011), and Tobramycin
(P < 0.011). Also, no relationship between the existence of Int3 and
antibiotics resistance was observed (P > 0.05).
4. Discussion
As presented in the Results section, over than 50% of clinical/en-
vironmental isolates were MDR. In clinical isolates, the most resistance
has been observed against Ticarcillin/Clavulanic Acid (75.8%), fol-
lowed by Aztreonam with a resistance of 72.4%. Also, in environmental
isolates, a highest resistance was observed against mentioned anti-
biotics (55%). The results of antibiotic resistance in clinical isolates are
similar to a study conducted in the north of Iran (Nikokar et al., 2013).
Interestingly, in most environmental isolates, the resistance rate against
mentioned antibiotics was higher than clinical isolates. Therefore, the
transmission of these isolates to patients leads to higher resistance.
For our knowledge, Carbapenems are the most eﬀective antibiotics
for the treatment of infections resulted from MDR strains; recently, the
increasing occurrence of carbapenem-resistant isolates of P. aeruginosa
has become a global concern (Rossolini et al., 2007). In the current
study, the frequency of resistance against Imipenem and Meropenem
was> 50%, but was not reported any resistance to Colistin in both
clinical and environmental strains. Thus, this antibiotic was an eﬀective
agent against P. aeruginosa in our area. Inconsistent with this ﬁnding, in
the research conducted by Josef Yayan et al. in 2015, no resistance was
described against Colistin in P. aeruginosa isolated of patients suﬀered
from pneumonia (Yayan et al., 2015). In compared to our ﬁndings, in a
study carried out in Turkey, a total of 60 P. aeruginosa achieved from
clinical samples, the maximum susceptibility reported to Colistin
(96%), and Piperacillin/Tazobactam (93%) (Gu et al., 2007).
Bioﬁlm formation of P. aeruginosa leads to loss of antibacterial
susceptibility and the use of more concentrations of antibiotics in the
treatment of infections caused by such isolates. Here we focused on the
correlation between bioﬁlm formation ability and the presence of re-
lated genes, including lasB, rhlA, and class 1, 2, and 3 integrons.
Diﬀerent classes of integrons, particularly; class 1 are involved in
resistance to various antibiotics that yields multi-drug resistance (MDR)
in P. aeruginosa. In our study, the prevalence of Int1, Int2, and Int3 in
Fig. 1. PCR ampliﬁcation of toxA, rhlA, lasB, Int1, Int2, and Int3 genes. A: lane1:50 bp DNA ladder, lane 2: Negative control, lane 3: Positive control, lanes 4–11: PCR
product from toxA positive isolates. B: lane 1:100 bp DNA ladder, lane 2: Negative control, lane 3: Positive control, lanes 4–9: PCR product from rhlA positive isolates.
C: lane1:100 bp DNA ladder, lane 2: Negative control, lane 3: Positive control, lanes 4–8: PCR product from lasB positive isolates. D: lane1:100 bp DNA ladder, lane 2:
Negative control, lane 3: Positive control, lane 4–10: PCR product from intI positive isolates. E: lane1:100 bp DNA ladder, lane 2: Negative control, lane 3: Positive
control, lanes 4–9: PCR product from Int2 positive isolates. F: lane 1:100 bp DNA ladder, lane 2: Positive control, lane 3: Negative control, lanes 4–8: PCR product
from Int3 positive isolates.
Table 4
The frequency distribution of bioﬁlm formation ability and bioﬁlm-related
genes in clinical and environmental isolates of P. aeruginosa.
Bioﬁlm LasB RhlA Int1 Int2 Int3
No % No % No % No % No %
No-bioﬁlm 3 100 2 66.7 0 0 1 33.3 0 0.0
Weak bioﬁlm 9 90.0 6 60.0 4 40.0 0 0.0 1 10.0
Moderate bioﬁlm 19 90.4 21 100 7 33.4 3 14.2 2 9.5
Strong bioﬁlm 43 97.7 44 100 38 88.3 18 40.9 8 18.1
P-value 0.52 0.00 0.00 0.02 0.66
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clinical isolates were 36 (63.1%), 16 (27.5%), and 4 (6.9%), respec-
tively. Also, in environmental isolates for the same genes, the pre-
valence has reported 13 (65%), 6 (30%), and 7 (35%), respectively.
Concerning the obtained results, the highest prevalence in clinical/en-
vironmental isolates was related to the class 1 integrons, which in the
other studies from diﬀerent regions of the world showed this issue (Kor
et al., 2013). Of course, this point should be noted that among in-
tegrons, class 1 has a more remarkably role in resistance (Manchanda
et al., 2010). Like our ﬁndings, in a study conducted by Esmaeili et al.,
in Iran on the strains isolated from patients admitted in the burn ward,
over than 90% of isolates had the class 1 integrons. But in contrast to
our ﬁndings, they didn't ﬁnd any correlation between this class of in-
tegrons and antimicrobial resistance.
The increasing in clinically-resistant strains likely is elucidated by
antibiotic selective pressure and the predominant existence of integrons
(Tenover, 2006). However, this is not always absolute and other me-
chanisms such as; the presence of purines, eﬄux pumps, plasmid ac-
quisition, and chromosomal mutation can cause antibiotic resistance
(Chen et al., 2009).
Generally, 43 (55.1%) of isolates were producers of strong bioﬁlm
in both environmental and clinical isolates. The prevalence of strong
bioﬁlms producers in clinical and environmental isolates were 35
(60.3%), and 8 (40%), respectively.
Generally, 96.2% of isolates (both of MDR, and Non-MDR) of clin-
ical and environmental isolates could produce the bioﬁlm. In con-
cordant to our results, the studies conducted by Jabalameli et al. and
Ghanbarzadeh et al. reported the 96.9%, and 92.4% of bioﬁlm forma-
tion in P. aeruginosa isolates, respectively (Corehtash et al., 2015;
Jabalameli et al., 2012). Of total 78 isolates, 49 (62.8%) were MDR, and
remaining 29 (37.2%) were Non-MDR. This high rate of MDR isolates in
the present study might due to the inappropriate use of antibiotics.
Overall, 46.8% of MDR isolates were producers of strong bioﬁlm, of
which, 34 (58.6%) were clinical isolates, and also 7 (35%) were en-
vironmental isolates. It showed a signiﬁcant correlation between MDR
form and bioﬁlm formation (P=0.00). But this association was not
found with Non-MDR isolates (P=0.2). In line with our study, others
showed a signiﬁcant correlation between MDR isolates with bioﬁlm
formation capability compared to susceptible strains (Abidi et al., 2013;
Corehtash et al., 2015).
Integrons like to plasmids and transposons have a great role in the
spreading of multi-drug resistance through mobile gene cassettes that
may contain resistance genes (Alikhani et al., 2017). As we know, the
class 1 integrons chieﬂy encode the resistance against Beta-lactamases,
Metallo-beta-lactamases, and aminoglycosides through mobile gene
cassettes that may contain resistance genes (Oteo et al., 2014).
Similarly, in the current study, a signiﬁcant correlation was found be-
tween Int1 and antibiotic resistance against Cefepime, Aztreonam,
Amikacin, Piperacillin, Ciproﬂoxacin, Ceftazidime, Imipenem, Genta-
micin, Meropenem, and Tobramycin in both environmental and clinical
isolates (P < 0.05), except such correlation was not found against
Tobramycin in environmental isolates (P > 0.05). Also, this correla-
tion was not reported between the prevalence of class 1 integrons with
resistance against Ticarcillin/Clavulanic Acid in both clinical and en-
vironmental isolates (P > 0.05). Our data are inconsistent with the
results of Gu et al. in which isolates with positivity for integrons showed
resistance of 88.9%, 92.6%, 88.9%, 48.1%, 59.3%, 25.9%, 63%, 66.7%,
and 92.6% against Ceftriaxone, Gentamicin, Ceftazidime, Cipro-
ﬂoxacin, Imipenem, Cefepime, Amikacin, and Cefotaxime, respectively.
As well as, in agreement with our ﬁndings, Moradian et al. showed that
the attendance of class1 integrons statistically had a signiﬁcant re-
lationship with resistance to Gentamicin, Ticarcillin, Imipenem, Ami-
kacin, Cefotaxime, and Oﬂoxacin (Shahandashti et al., 2012).
The class 1 integron is accountable for maximum cases of antibiotic
resistance and relatedness to the maximum variety of gene cassettes in a
broad range of species (Boucher et al., 2007). Nonetheless, there are
other classes of integrons including classes 2 and 3 with conferring the
antibiotic resistance. As we know, the class 1 integrons chieﬂy encode
the resistance against Beta-lactamases, Metallo-beta-lactamases, and
aminoglycosides through mobile gene cassettes that may contain re-
sistance genes (Gaze et al., 2005). Classes 2 and 3 integrons share their
cassette pool with the class1 integrons (Michael et al., 2014).
Our results showed only statistically signiﬁcant association between
the presence of Int2 and resistance against Aztreonam (P < 0.045),
while, didn't show any association between the presence of Int2 and
resistance against other antibiotics in clinical isolates used in current
study (P > 0.05). But in environmental isolates, such a correlation was
seen for Meropenem (P < 0.011), and Tobramycin (P < 0.011).
While, about 41% of isolates were positive for presence of Int2, but they
didn't show any correlation with resistance against most of the anti-
biotics used. This subject possibly referred to this fact that the integron
integrase gene of clinical class 2 integrons is silent, this limits the
capability of the integrons to obtain and reorganize gene cassettes
(White et al., 2001), and that their range of cassette functions than
those of class 1 integrons is greatly more restricted (Biskri and Mazel,
2003).
Our results reported an occurrence of 18.1% of Int3 in isolates
producing the strong bioﬁlm, while, were not found a signiﬁcant as-
sociation between antibiotics resistance and the existence of Int3 in
clinical and environmental isolates. The prevalence of class 3 integrons
was reported high in the current study as compared with other studies
Table 5
Correlation between classes 1, 2, and 3 integrons and antibiotic resistance.
Antibiotics Clinical Environmental
IntI IntII IntIII IntI IntII IntIII
N (%) P-value N (%) P-value N (%) P-value N (%) P-value N (%) P-value N (%) P-value
CO 0 (0) – 0 (0) – 0 (0) – 0 (0) – 0 (0) – 0 (0) –
CPM 27 (46.4) 0.001 11 (19) 0.239 3 (5.2) 0.615 8 (40) 0.35 4 (20) 0.628 4 (20) 1.000
ATM 30 (52.6) 0.017 15 (25.9) 0.045 4 (6.9) 0.567 10 (50) 0.017 5 (25) 0.157 5 (25) 0.374
AK 24 (42.1) 0.001 19 (15.5) 0.561 3 (5.2) 0.344 9 (45) 0.005 5 (25) 0.050 5 (25) 0.160
PRL 25 (43.9) 0.028 11 (19) 0.385 3 (5.2) 0.635 8 (40) 0.070 5 (25) 0.050 4 (20) 0.642
CIP 28 (49.1) 0.004 11 (19) 0.764 3 (5.2) 1.000 10 (50) 0.003 5 (25) 0.141 5 (25) 0.350
CAZ 25 (43.9) 0.001 11 (19) 0.079 3 (5.2) 0.344 7 (35) 0.370 4 (20) 0.336 6 (30) 0.117
IMI 24 (42.1) 0.007 9 (15.5) 1.000 3 (5.2) 0.615 10 (50) 0.003 5 (25) 0.141 5 (25) 0.350
GM 24 (42.1) 0.001 10 (17.2) 0.140 3 (5.2) 0.316 10 (50) 0.017 5 (25) 0.157 5 (25) 0.374
MEM 25 (43.9) 0.001 10 (17.2) 0.385 3 (5.2) 0.612 8 (40) 0.015 5 (25) 0.018 3 (15) 1.000
TN 26 (45.6) 0.001 9 (15.5) 0.561 3 (5.2) 0.333 8 (40) 0.015 5 (25) 0.018 4 (20) 0.356
TIM 29 (50.9) 0.34 14 (24.1) 0.308 4 (6.9) 0.563 9 (45) 0.16 5 (25) 0.157 5 (25) 0.374
Note: CO: Colistin, CPM: Cefepime, ATM: Azteronam, AK: Amikacin, PRL: Piperacilin, CIP: Ciproﬂoxacin, CAZ: Ceftazidime, IMI: Imipenem, GM: Gentamicin, MEM:
Meropenem, TN: Tobramycin, TIM: Ticarcilin/Calvulanic Acid.
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(Shibata et al., 2003), although we not found a signiﬁcant diﬀerence
between the presence of class 3 integrons and drug resistance.
Our ﬁndings showed that source of clinical isolates is possibly from
the environment, so, appropriate disinfection should be taken to pre-
vent the transmission of environmental strains to patients and trans-
mission of pathogens from patients to the environment and hospital
devices. However, once such resistant strains have emerged, either the
host strains can spread among patients and the hospital environment or
the resistance can disseminate among bacterial isolates (Livermore,
2002).
Also, a signiﬁcant correlation was observed between Int1, 2, and
rhlA genes with bioﬁlm formation capability of isolates (P=0.02).
Based on results, among the isolates involved in producing bioﬁlm, the
rate of these genes was high. It is known that antibiotic concentration
needed to overcome colonization of bacteria in the bioﬁlm is 100 to
1000 fold more than their planktonic type (Whiteley et al., 2001).
Another study suggests that antibiotic resistance in non-integrons-en-
coding isolates may be owing to bioﬁlm formation (Aryanezhad et al.,
2016). As well, an interesting ﬁnding in our study was that we did not
found any correlation between the presence of lasB gene and bioﬁlm
formation. This diﬀerence possibly attributed to this fact that other
classes of las operon such as lasR-lasI and other genes may be involved
in this subject (Pye, 2013). The lasR-lasI QS system in Pseudomonas
aeruginosa will be activated when attachment becomes irreversible and
rhlR-rhlI will be activated during the ﬁrst maturation stage (Finelli
et al., 2003).
Finally, our results may be useful in the development of disinfection
policies to control hospital-acquired infections.
5. Conclusions
In total, > 50% of both environmental and clinical isolates were
producers of strong bioﬁlm. Also, a signiﬁcant correlation was observed
between Int1, Int2, and rhlA genes with bioﬁlm formation capability of
isolates. This fact showed that the source of clinical isolates may be
from the environment. Therefore, the necessary hygiene measurements
should be taken for the prevention of transferring the environmental
isolates to hospitalized patients, especially in critical wards such as ICU
and burn units. No signiﬁcant correlation was observed between lasB
gene with bioﬁlm formation capability, So, other genes may be in-
volved in initiating bioﬁlm formation.
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